These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32270628)

  • 41. Extremely low therapeutic doses of acenocoumarol in a patient with
    Chaidaroglou A; Kanellopoulou T; Panopoulos G; Stavridis G; Degiannis D
    Pharmacogenomics; 2019 Apr; 20(5):311-317. PubMed ID: 30983536
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of CYP2C9 and VKORC1 Gene Variants on Warfarin Response in Patients with Continuous-Flow Left Ventricular Assist Devices.
    Topkara VK; Knotts RJ; Jennings DL; Garan AR; Levin AP; Breskin A; Castagna F; Cagliostro B; Yuzefpolskaya M; Takeda K; Takayama H; Uriel N; Mancini DM; Eisenberger A; Naka Y; Colombo PC; Jorde UP
    ASAIO J; 2016; 62(5):558-64. PubMed ID: 27258224
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
    Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
    Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements.
    Zhou L; Ding Y; Gao Y; Yang B; Bao J; Ma J
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):1-9. PubMed ID: 31914334
    [No Abstract]   [Full Text] [Related]  

  • 45. Genes affecting warfarin response-interactive or additive?
    Cavallari LH; Duarte JD
    J Clin Pharmacol; 2015 Mar; 55(3):258-60. PubMed ID: 25385663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial.
    Zambon CF; Pengo V; Moz S; Bozzato D; Fogar P; Padoan A; Plebani M; Groppa F; De Rosa G; Padrini R
    Eur J Clin Pharmacol; 2018 May; 74(5):571-582. PubMed ID: 29396738
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
    Arwood MJ; Deng J; Drozda K; Pugach O; Nutescu EA; Schmidt S; Duarte JD; Cavallari LH
    Clin Pharmacol Ther; 2017 May; 101(5):675-683. PubMed ID: 28032893
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
    Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
    Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
    Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
    J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery.
    Abohelaika S; Wynne H; Avery P; Kampouraki E; Kamali F
    Thromb Res; 2018 Nov; 171():167-170. PubMed ID: 30321703
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
    Zhuang W; Wu D; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.
    Dilge Taşkın B; Kula S; Ergün MA; Altun D; Olguntürk R; Tunaoğlu FS; Oğuz AD; Gürsel T
    Anatol J Cardiol; 2016 Oct; 16(10):791-796. PubMed ID: 27182616
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.
    Nagler M; Angelillo-Scherrer A; Méan M; Limacher A; Abbal C; Righini M; Beer JH; Osterwalder J; Frauchiger B; Aschwanden M; Matter CM; Kucher N; Cornuz J; Banyai M; Husmann M; Staub D; Mazzolai L; Hugli O; Rodondi N; Aujesky D
    J Thromb Haemost; 2017 Nov; 15(11):2165-2175. PubMed ID: 28834238
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up.
    Wypasek E; Mazur P; Bochenek M; Awsiuk M; Grudzien G; Plicner A; Undas A
    J Physiol Pharmacol; 2016 Jun; 67(3):385-93. PubMed ID: 27511999
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals].
    Benavides F; Grossman N; Poggi H; Nieto E; Bertrán A; Araos D; Vásquez M; Ibarra I; Cáceres F; Espinoza K; Lagos M; Repetto M G
    Rev Med Chil; 2015 Nov; 143(11):1369-76. PubMed ID: 26757860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.